Chromosome mis-segregation and cytokinesis failure in trisomic human cells

  1. Joshua M Nicholson
  2. Joana C Macedo
  3. Aaron J Mattingly
  4. Darawalee Wangsa
  5. Jordi Camps
  6. Vera Lima
  7. Ana M Gomes
  8. Sofia Dória
  9. Thomas Ried
  10. Elsa Logarinho
  11. Daniela Cimini  Is a corresponding author
  1. Virginia Tech, United States
  2. Universidade do Porto, Portugal
  3. University of California, San Francisco, United States
  4. National Institutes of Health, United States
  5. Institut D'Investigacions Biomèdiques August Pi i Sunyer, Spain

Abstract

Cancer cells display aneuploid karyotypes and typically mis-segregate chromosomes at high rates, a phenotype referred to as chromosomal instability (CIN). To test the effects of aneuploidy on chromosome segregation and other mitotic phenotypes we used the colorectal cancer cell line DLD1 (2n=46) and two variants with trisomy 7 or 13 (DLD1+7 and DLD1+13), as well as euploid and trisomy 13 amniocytes (AF and AF+13). We found that trisomic cells displayed higher rates of chromosome mis-segregation compared to their euploid counterparts. Furthermore, cells with trisomy 13 displayed a distinctive cytokinesis failure phenotype. We showed that up-regulation of SPG20 expression, brought about by trisomy 13 in DLD1+13 and AF+13 cells, is both required and sufficient for the cytokinesis failure phenotype. Overall, our study shows that aneuploidy can induce chromosome mis-segregation. Moreover, we identified a trisomy 13-specific mitotic phenotype that is driven by up-regulation of a gene encoded on the aneuploid chromosome.

Article and author information

Author details

  1. Joshua M Nicholson

    Department of Biological Sciences, Virginia Tech, Blacksburg, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Joana C Macedo

    Aging and Aneuploidy Laboratory, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  3. Aaron J Mattingly

    Cell and Tissue Biology, School of Dentistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Darawalee Wangsa

    Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Jordi Camps

    Gastrointestinal and Pancreatic Oncology Group, Hospital Clínic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  6. Vera Lima

    Department of Genetics, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  7. Ana M Gomes

    Aging and Aneuploidy Laboratory, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  8. Sofia Dória

    Department of Genetics, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  9. Thomas Ried

    Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Elsa Logarinho

    Aging and Aneuploidy Laboratory, Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal
    Competing interests
    The authors declare that no competing interests exist.
  11. Daniela Cimini

    Department of Biological Sciences, Virginia Tech, Blacksburg, United States
    For correspondence
    cimini@vt.edu
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Jon Pines, The Gurdon Institute, United Kingdom

Ethics

Human subjects: The study acknowledged the ethics guidelines under national rules and accordingly to the principles of the Declaration of Helsinki, and was approved by the Ethics Committee of Hospital de S. Jo�o-Porto (dispatch 14 Nov 2012) (approval number 237/2012). Informed consent forms with detailed information were provided to all patients. The study did not imply collection of extra material from the healthy donor females (only surplus cells/tissues were used); the study didn't bring any direct benefits to the volunteers; there were no risks or costs for the volunteers; there was no access to patient clinical data (samples were obtained in anonymous form from the Hospital Genetics Department); participation was volunteer and free to be interrupted at any moment; there are no ethical impacts predicted; there will be no commercial interests.

Version history

  1. Received: October 7, 2014
  2. Accepted: May 1, 2015
  3. Accepted Manuscript published: May 5, 2015 (version 1)
  4. Version of Record published: May 27, 2015 (version 2)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 14,739
    views
  • 1,161
    downloads
  • 86
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Joshua M Nicholson
  2. Joana C Macedo
  3. Aaron J Mattingly
  4. Darawalee Wangsa
  5. Jordi Camps
  6. Vera Lima
  7. Ana M Gomes
  8. Sofia Dória
  9. Thomas Ried
  10. Elsa Logarinho
  11. Daniela Cimini
(2015)
Chromosome mis-segregation and cytokinesis failure in trisomic human cells
eLife 4:e05068.
https://doi.org/10.7554/eLife.05068

Share this article

https://doi.org/10.7554/eLife.05068

Further reading

    1. Cell Biology
    Makiko Kashio, Sandra Derouiche ... Makoto Tominaga
    Research Article

    Reports indicate that an interaction between TRPV4 and anoctamin 1 (ANO1) could be widely involved in water efflux of exocrine glands, suggesting that the interaction could play a role in perspiration. In secretory cells of sweat glands present in mouse foot pads, TRPV4 clearly colocalized with cytokeratin 8, ANO1, and aquaporin-5 (AQP5). Mouse sweat glands showed TRPV4-dependent cytosolic Ca2+ increases that were inhibited by menthol. Acetylcholine-stimulated sweating in foot pads was temperature-dependent in wild-type, but not in TRPV4-deficient mice and was inhibited by menthol both in wild-type and TRPM8KO mice. The basal sweating without acetylcholine stimulation was inhibited by an ANO1 inhibitor. Sweating could be important for maintaining friction forces in mouse foot pads, and this possibility is supported by the finding that wild-type mice climbed up a slippery slope more easily than TRPV4-deficient mice. Furthermore, TRPV4 expression was significantly higher in controls and normohidrotic skin from patients with acquired idiopathic generalized anhidrosis (AIGA) compared to anhidrotic skin from patients with AIGA. Collectively, TRPV4 is likely involved in temperature-dependent perspiration via interactions with ANO1, and TRPV4 itself or the TRPV4/ANO 1 complex would be targeted to develop agents that regulate perspiration.

    1. Cell Biology
    Yuki Date, Yukiko Sasazawa ... Shinji Saiki
    Research Article Updated

    The autophagy-lysosome pathway plays an indispensable role in the protein quality control by degrading abnormal organelles and proteins including α-synuclein (αSyn) associated with the pathogenesis of Parkinson’s disease (PD). However, the activation of this pathway is mainly by targeting lysosomal enzymic activity. Here, we focused on the autophagosome-lysosome fusion process around the microtubule-organizing center (MTOC) regulated by lysosomal positioning. Through high-throughput chemical screening, we identified 6 out of 1200 clinically approved drugs enabling the lysosomes to accumulate around the MTOC with autophagy flux enhancement. We further demonstrated that these compounds induce the lysosomal clustering through a JIP4-TRPML1-dependent mechanism. Among them, the lysosomal-clustering compound albendazole promoted the autophagy-dependent degradation of Triton-X-insoluble, proteasome inhibitor-induced aggregates. In a cellular PD model, albendazole boosted insoluble αSyn degradation. Our results revealed that lysosomal clustering can facilitate the breakdown of protein aggregates, suggesting that lysosome-clustering compounds may offer a promising therapeutic strategy against neurodegenerative diseases characterized by the presence of aggregate-prone proteins.